Bristol Director Cornelius Will Serve As Interim CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol’s Board of Directors announces CEO Peter Dolan to leave, effective immediately, as well as general counsel Richard Willard.
|
Bristol-Myers Squibb Director James Cornelius will replace CEO Peter Dolan as interim CEO, effective immediately, the company's Board of Directors announced Sept. 12. Cornelius previously served as Lilly's chief financial officer before becoming chairman of Guidant; the device firm was spun off from Lilly in 1994. Richard Willard will also leave his position of senior vice president and general counsel, effective immediately. Sandra Leung, VP and corporate secretary will act as interim general counsel. The Board made its decision following the Sept. 11 recommendation of former Federal Judge Frederick B. Lacey, who serves as the company's Monitor under its deferred prosecution agreement with the office of the U.S. Attorney for the District of New Jersey. [Publisher's Note: F-D-C Reports is planning an audio conference on October 12, 2006, entitled " Patentbusters: The Uncertain Future of Branded and Generic Drugs in the Wake of Plavix and Apotex." For more details please contact [email protected].] |